APO Research
Talk to an analyst

APO RESEARCH · REPORT

VEGF Inhibitors for Cancer

Compare research editions
View pricing & licenses

Selected research

Industry Research

VEGF Inhibitors for Cancer Industry Research Report 2026

27 December 2025126 pages

Choose your research edition.

Industry ResearchVEGF Inhibitors for Cancer Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal VEGF Inhibitors for Cancer Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal VEGF Inhibitors for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VEGF Inhibitors for Cancer Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal VEGF Inhibitors for Cancer Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global VEGF Inhibitors for Cancer market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for VEGF Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for VEGF Inhibitors for Cancer is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for VEGF Inhibitors for Cancer is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of VEGF Inhibitors for Cancer include Amgen, Amneal Pharmaceuticals, Celltrion Healthcare, Eli Lilly, Pfizer, Roche, Sanofi, Boan Biotech and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global VEGF Inhibitors for Cancer market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

VEGF Inhibitors for Cancer Market by Company

Amgen

Amneal Pharmaceuticals

Celltrion Healthcare

Eli Lilly

Pfizer

Roche

Sanofi

Boan Biotech

Jiangsu Hengrui Pharmaceuticals

Qilu Pharma

SinoCellTech

Innovent

Chia Tai Tianqing

VEGF Inhibitors for Cancer Segment by Type

Ramucirumab

Ramucirumab

Aflibercept

Other

VEGF Inhibitors for Cancer Segment by Application

Metastatic colorectal cancer

Metastatic Non-small Cell Lung Cancer

Cervical Cancer

Recurrent Glioblastoma

Other

VEGF Inhibitors for Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGF Inhibitors for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VEGF Inhibitors for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGF Inhibitors for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of VEGF Inhibitors for Cancer manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of VEGF Inhibitors for Cancer by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of VEGF Inhibitors for Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global VEGF Inhibitors for Cancer Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global VEGF Inhibitors for Cancer Sales (K Units) of Manufacturers (2021-2026) Table 7. Global VEGF Inhibitors for Cancer Sales Market Share by Manufacturers (2021-2026) Table 8. Global VEGF Inhibitors for Cancer Revenue of Manufacturers (2021-2026) Table 9. Global VEGF Inhibitors for Cancer Revenue Share by Manufacturers (2021-2026) Table 10. Global Market VEGF Inhibitors for Cancer Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global VEGF Inhibitors for Cancer Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of VEGF Inhibitors for Cancer, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of VEGF Inhibitors for Cancer, Product Type & Application Table 14. Global VEGF Inhibitors for Cancer Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global VEGF Inhibitors for Cancer by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Amgen Company Information Table 19. Amgen Business Overview Table 20. Amgen VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Amgen VEGF Inhibitors for Cancer Product Portfolio Table 22. Amgen Recent Developments Table 23. Amneal Pharmaceuticals Company Information Table 24. Amneal Pharmaceuticals Business Overview Table 25. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio Table 27. Amneal Pharmaceuticals Recent Developments Table 28. Celltrion Healthcare Company Information Table 29. Celltrion Healthcare Business Overview Table 30. Celltrion Healthcare VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Celltrion Healthcare VEGF Inhibitors for Cancer Product Portfolio Table 32. Celltrion Healthcare Recent Developments Table 33. Eli Lilly Company Information Table 34. Eli Lilly Business Overview Table 35. Eli Lilly VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Eli Lilly VEGF Inhibitors for Cancer Product Portfolio Table 37. Eli Lilly Recent Developments Table 38. Pfizer Company Information Table 39. Pfizer Business Overview Table 40. Pfizer VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Pfizer VEGF Inhibitors for Cancer Product Portfolio Table 42. Pfizer Recent Developments Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Roche VEGF Inhibitors for Cancer Product Portfolio Table 47. Roche Recent Developments Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sanofi VEGF Inhibitors for Cancer Product Portfolio Table 52. Sanofi Recent Developments Table 53. Boan Biotech Company Information Table 54. Boan Biotech Business Overview Table 55. Boan Biotech VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Boan Biotech VEGF Inhibitors for Cancer Product Portfolio Table 57. Boan Biotech Recent Developments Table 58. Jiangsu Hengrui Pharmaceuticals Company Information Table 59. Jiangsu Hengrui Pharmaceuticals Business Overview Table 60. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio Table 62. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 63. Qilu Pharma Company Information Table 64. Qilu Pharma Business Overview Table 65. Qilu Pharma VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Qilu Pharma VEGF Inhibitors for Cancer Product Portfolio Table 67. Qilu Pharma Recent Developments Table 68. SinoCellTech Company Information Table 69. SinoCellTech Business Overview Table 70. SinoCellTech VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. SinoCellTech VEGF Inhibitors for Cancer Product Portfolio Table 72. SinoCellTech Recent Developments Table 73. Innovent Company Information Table 74. Innovent Business Overview Table 75. Innovent VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Innovent VEGF Inhibitors for Cancer Product Portfolio Table 77. Innovent Recent Developments Table 78. Chia Tai Tianqing Company Information Table 79. Chia Tai Tianqing Business Overview Table 80. Chia Tai Tianqing VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Chia Tai Tianqing VEGF Inhibitors for Cancer Product Portfolio Table 82. Chia Tai Tianqing Recent Developments Table 83. Global VEGF Inhibitors for Cancer Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global VEGF Inhibitors for Cancer Sales by Region (2021-2026) & (K Units) Table 85. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2021-2026) Table 86. Global VEGF Inhibitors for Cancer Sales by Region (2027-2032) & (K Units) Table 87. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2027-2032) Table 88. Global VEGF Inhibitors for Cancer Revenue by Region (2021-2026) & (US$ Million) Table 89. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2021-2026) Table 90. Global VEGF Inhibitors for Cancer Revenue by Region (2027-2032) & (US$ Million) Table 91. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2027-2032) Table 92. North America VEGF Inhibitors for Cancer Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 94. North America VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 95. North America VEGF Inhibitors for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 96. North America VEGF Inhibitors for Cancer Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe VEGF Inhibitors for Cancer Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 99. Europe VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 100. Europe VEGF Inhibitors for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe VEGF Inhibitors for Cancer Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific VEGF Inhibitors for Cancer Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 104. Asia Pacific VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 105. Asia Pacific VEGF Inhibitors for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific VEGF Inhibitors for Cancer Revenue by Country (2027-2032) & (US$ Million) Table 107. South America VEGF Inhibitors for Cancer Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 109. South America VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 110. South America VEGF Inhibitors for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 111. South America VEGF Inhibitors for Cancer Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 114. Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 115. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (2027-2032) & (US$ Million) Table 117. Global VEGF Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 118. Global VEGF Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 119. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021-2026) Table 120. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2027-2032) Table 121. Global VEGF Inhibitors for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 122. Global VEGF Inhibitors for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 123. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021-2026) Table 124. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2027-2032) Table 125. Global VEGF Inhibitors for Cancer Price by Type (2021-2026) & (US$/Unit) Table 126. Global VEGF Inhibitors for Cancer Price by Type (2027-2032) & (US$/Unit) Table 127. Global VEGF Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 128. Global VEGF Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 129. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021-2026) Table 130. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2027-2032) Table 131. Global VEGF Inhibitors for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 132. Global VEGF Inhibitors for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 133. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021-2026) Table 134. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2027-2032) Table 135. Global VEGF Inhibitors for Cancer Price by Application (2021-2026) & (US$/Unit) Table 136. Global VEGF Inhibitors for Cancer Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. VEGF Inhibitors for Cancer Distributors List Table 140. VEGF Inhibitors for Cancer Customers List Table 141. VEGF Inhibitors for Cancer Industry Trends Table 142. VEGF Inhibitors for Cancer Industry Drivers Table 143. VEGF Inhibitors for Cancer Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. VEGF Inhibitors for Cancer Product Image Figure 5. Global VEGF Inhibitors for Cancer Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global VEGF Inhibitors for Cancer Market Size (2021-2032) & (US$ Million) Figure 7. Global VEGF Inhibitors for Cancer Sales (2021-2032) & (K Units) Figure 8. Global VEGF Inhibitors for Cancer Average Price (US$/Unit) & (2021-2032) Figure 9. Ramucirumab Product Image Figure 10. Ramucirumab Product Image Figure 11. Aflibercept Product Image Figure 12. Other Product Image Figure 13. Metastatic colorectal cancer Product Image Figure 14. Metastatic Non-small Cell Lung Cancer Product Image Figure 15. Cervical Cancer Product Image Figure 16. Recurrent Glioblastoma Product Image Figure 17. Other Product Image Figure 18. Global VEGF Inhibitors for Cancer Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of VEGF Inhibitors for Cancer, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 VEGF Inhibitors for Cancer Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global VEGF Inhibitors for Cancer Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global VEGF Inhibitors for Cancer Sales by Region in 2025 Figure 24. Global VEGF Inhibitors for Cancer Revenue by Region in 2025 Figure 25. North America VEGF Inhibitors for Cancer Market Size by Country in 2025 Figure 26. North America VEGF Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 27. North America VEGF Inhibitors for Cancer Revenue Market Share by Country (2021-2032) Figure 28. United States VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe VEGF Inhibitors for Cancer Market Size by Country in 2025 Figure 32. Europe VEGF Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 33. Europe VEGF Inhibitors for Cancer Revenue Market Share by Country (2021-2032) Figure 34. Germany VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific VEGF Inhibitors for Cancer Market Size by Country in 2025 Figure 45. Asia Pacific VEGF Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific VEGF Inhibitors for Cancer Revenue Market Share by Country (2021-2032) Figure 47. China VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America VEGF Inhibitors for Cancer Market Size by Country in 2025 Figure 56. South America VEGF Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 57. South America VEGF Inhibitors for Cancer Revenue Market Share by Country (2021-2032) Figure 58. Brazil VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa VEGF Inhibitors for Cancer Market Size by Country in 2025 Figure 62. Middle East and Africa VEGF Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa VEGF Inhibitors for Cancer Revenue Market Share by Country (2021-2032) Figure 64. Egypt VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries VEGF Inhibitors for Cancer Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021-2032) Figure 70. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021-2032) Figure 71. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Type (2021-2032) Figure 72. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021-2032) Figure 73. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021-2032) Figure 74. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Application (2021-2032) Figure 75. VEGF Inhibitors for Cancer Value Chain Figure 76. VEGF Inhibitors for Cancer Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. VEGF Inhibitors for Cancer Industry Opportunities and Challenges

Scope & coverage.

Types
  • Ramucirumab
  • Ramucirumab
  • Aflibercept
  • Other
Applications
  • Metastatic colorectal cancer
  • Metastatic Non-small Cell Lung Cancer
  • Cervical Cancer
  • Recurrent Glioblastoma
  • Other
Companies covered
  • Amgen
  • Amneal Pharmaceuticals
  • Celltrion Healthcare
  • Eli Lilly
  • Pfizer
  • Roche
  • Sanofi
  • Boan Biotech
  • Jiangsu Hengrui Pharmaceuticals
  • Qilu Pharma
  • SinoCellTech
  • Innovent
  • Chia Tai Tianqing

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global VEGF Inhibitors for Cancer Market Size (2021-2032)
  4. 2.2.2 Global VEGF Inhibitors for Cancer Sales (2021-2032)
  5. 2.2.3 Global VEGF Inhibitors for Cancer Market Average Price (2021-2032)
  6. 2.3 VEGF Inhibitors for Cancer by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Ramucirumab
  9. 2.3.3 Ramucirumab
  10. 2.3.4 Aflibercept
  11. 2.3.5 Other
  12. 2.4 VEGF Inhibitors for Cancer by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Metastatic colorectal cancer
  15. 2.4.3 Metastatic Non-small Cell Lung Cancer
  16. 2.4.4 Cervical Cancer
  17. 2.4.5 Recurrent Glioblastoma
  18. 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global VEGF Inhibitors for Cancer Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global VEGF Inhibitors for Cancer Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global VEGF Inhibitors for Cancer Revenue of Manufacturers (2021-2026)
  4. 3.4 Global VEGF Inhibitors for Cancer Average Price by Manufacturers (2021-2026)
  5. 3.5 Global VEGF Inhibitors for Cancer Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of VEGF Inhibitors for Cancer, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of VEGF Inhibitors for Cancer, Product Type & Application
  8. 3.8 Global Manufacturers of VEGF Inhibitors for Cancer, Established Date
  9. 3.9 Global VEGF Inhibitors for Cancer Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Amgen
  2. 4.1.1 Amgen Company Information
  3. 4.1.2 Amgen Business Overview
  4. 4.1.3 Amgen VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Amgen VEGF Inhibitors for Cancer Product Portfolio
  6. 4.1.5 Amgen Recent Developments
  7. 4.2 Amneal Pharmaceuticals
  8. 4.2.1 Amneal Pharmaceuticals Company Information
  9. 4.2.2 Amneal Pharmaceuticals Business Overview
  10. 4.2.3 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio
  12. 4.2.5 Amneal Pharmaceuticals Recent Developments
  13. 4.3 Celltrion Healthcare
  14. 4.3.1 Celltrion Healthcare Company Information
  15. 4.3.2 Celltrion Healthcare Business Overview
  16. 4.3.3 Celltrion Healthcare VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Celltrion Healthcare VEGF Inhibitors for Cancer Product Portfolio
  18. 4.3.5 Celltrion Healthcare Recent Developments
  19. 4.4 Eli Lilly
  20. 4.4.1 Eli Lilly Company Information
  21. 4.4.2 Eli Lilly Business Overview
  22. 4.4.3 Eli Lilly VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Eli Lilly VEGF Inhibitors for Cancer Product Portfolio
  24. 4.4.5 Eli Lilly Recent Developments
  25. 4.5 Pfizer
  26. 4.5.1 Pfizer Company Information
  27. 4.5.2 Pfizer Business Overview
  28. 4.5.3 Pfizer VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Pfizer VEGF Inhibitors for Cancer Product Portfolio
  30. 4.5.5 Pfizer Recent Developments
  31. 4.6 Roche
  32. 4.6.1 Roche Company Information
  33. 4.6.2 Roche Business Overview
  34. 4.6.3 Roche VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Roche VEGF Inhibitors for Cancer Product Portfolio
  36. 4.6.5 Roche Recent Developments
  37. 4.7 Sanofi
  38. 4.7.1 Sanofi Company Information
  39. 4.7.2 Sanofi Business Overview
  40. 4.7.3 Sanofi VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sanofi VEGF Inhibitors for Cancer Product Portfolio
  42. 4.7.5 Sanofi Recent Developments
  43. 4.8 Boan Biotech
  44. 4.8.1 Boan Biotech Company Information
  45. 4.8.2 Boan Biotech Business Overview
  46. 4.8.3 Boan Biotech VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Boan Biotech VEGF Inhibitors for Cancer Product Portfolio
  48. 4.8.5 Boan Biotech Recent Developments
  49. 4.9 Jiangsu Hengrui Pharmaceuticals
  50. 4.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 4.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 4.9.3 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio
  54. 4.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 4.10 Qilu Pharma
  56. 4.10.1 Qilu Pharma Company Information
  57. 4.10.2 Qilu Pharma Business Overview
  58. 4.10.3 Qilu Pharma VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Qilu Pharma VEGF Inhibitors for Cancer Product Portfolio
  60. 4.10.5 Qilu Pharma Recent Developments
  61. 4.11 SinoCellTech
  62. 4.11.1 SinoCellTech Company Information
  63. 4.11.2 SinoCellTech Business Overview
  64. 4.11.3 SinoCellTech VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 SinoCellTech VEGF Inhibitors for Cancer Product Portfolio
  66. 4.11.5 SinoCellTech Recent Developments
  67. 4.12 Innovent
  68. 4.12.1 Innovent Company Information
  69. 4.12.2 Innovent Business Overview
  70. 4.12.3 Innovent VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Innovent VEGF Inhibitors for Cancer Product Portfolio
  72. 4.12.5 Innovent Recent Developments
  73. 4.13 Chia Tai Tianqing
  74. 4.13.1 Chia Tai Tianqing Company Information
  75. 4.13.2 Chia Tai Tianqing Business Overview
  76. 4.13.3 Chia Tai Tianqing VEGF Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Chia Tai Tianqing VEGF Inhibitors for Cancer Product Portfolio
  78. 4.13.5 Chia Tai Tianqing Recent Developments
5 Global VEGF Inhibitors for Cancer Market Scenario by Region
  1. 5.1 Global VEGF Inhibitors for Cancer Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global VEGF Inhibitors for Cancer Sales by Region: 2021-2032
  3. 5.2.1 Global VEGF Inhibitors for Cancer Sales by Region: 2021-2026
  4. 5.2.2 Global VEGF Inhibitors for Cancer Sales by Region: 2027-2032
  5. 5.3 Global VEGF Inhibitors for Cancer Revenue by Region: 2021-2032
  6. 5.3.1 Global VEGF Inhibitors for Cancer Revenue by Region: 2021-2026
  7. 5.3.2 Global VEGF Inhibitors for Cancer Revenue by Region: 2027-2032
  8. 5.4 North America VEGF Inhibitors for Cancer Market Facts & Figures by Country
  9. 5.4.1 North America VEGF Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America VEGF Inhibitors for Cancer Sales by Country (2021-2032)
  11. 5.4.3 North America VEGF Inhibitors for Cancer Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe VEGF Inhibitors for Cancer Market Facts & Figures by Country
  16. 5.5.1 Europe VEGF Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe VEGF Inhibitors for Cancer Sales by Country (2021-2032)
  18. 5.5.3 Europe VEGF Inhibitors for Cancer Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific VEGF Inhibitors for Cancer Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific VEGF Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific VEGF Inhibitors for Cancer Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific VEGF Inhibitors for Cancer Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America VEGF Inhibitors for Cancer Market Facts & Figures by Country
  41. 5.7.1 South America VEGF Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America VEGF Inhibitors for Cancer Sales by Country (2021-2032)
  43. 5.7.3 South America VEGF Inhibitors for Cancer Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa VEGF Inhibitors for Cancer Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa VEGF Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global VEGF Inhibitors for Cancer Sales by Type (2021-2032)
  2. 6.1.1 Global VEGF Inhibitors for Cancer Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021-2032)
  4. 6.2 Global VEGF Inhibitors for Cancer Revenue by Type (2021-2032)
  5. 6.2.1 Global VEGF Inhibitors for Cancer Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021-2032)
  7. 6.3 Global VEGF Inhibitors for Cancer Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global VEGF Inhibitors for Cancer Sales by Application (2021-2032)
  2. 7.1.1 Global VEGF Inhibitors for Cancer Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021-2032)
  4. 7.2 Global VEGF Inhibitors for Cancer Revenue by Application (2021-2032)
  5. 7.2.1 Global VEGF Inhibitors for Cancer Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021-2032)
  7. 7.3 Global VEGF Inhibitors for Cancer Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 VEGF Inhibitors for Cancer Value Chain Analysis
  2. 8.1.1 VEGF Inhibitors for Cancer Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 VEGF Inhibitors for Cancer Production Mode & Process
  5. 8.2 VEGF Inhibitors for Cancer Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 VEGF Inhibitors for Cancer Distributors
  8. 8.2.3 VEGF Inhibitors for Cancer Customers
9 Global VEGF Inhibitors for Cancer Analyzing Market Dynamics
  1. 9.1 VEGF Inhibitors for Cancer Industry Trends
  2. 9.2 VEGF Inhibitors for Cancer Industry Drivers
  3. 9.3 VEGF Inhibitors for Cancer Industry Opportunities and Challenges
  4. 9.4 VEGF Inhibitors for Cancer Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst